Tags: Cancer | lung | cancer | drug | meets | goal | trial

New Lung Cancer Drug Meets Goals in Late-Stage Trial

New Lung Cancer Drug Meets Goals in Late-Stage Trial
(Copyright iStock)

Tuesday, 19 July 2016 09:05 AM

AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study.

The tablet, which has won early approval from both U.S. and European regulators, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs.

AstraZeneca said Tagrisso showed superior progression-free survival compared to standard platinum-based chemotherapy.

The trial assessed Tagrisso's efficacy and safety as a second-line treatment for certain kinds of lung cancer, the drugmaker said.

Second-line therapies are used when initial, or first-line, treatments do not produce adequate results.

AstraZeneca said a full evaluation of the data is ongoing.

© 2021 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study. The tablet, which has won early approval from both U.S. and European regulators, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following...
lung, cancer, drug, meets, goal, trial
104
2016-05-19
Tuesday, 19 July 2016 09:05 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved